Patterns of antihypertensive therapy in new users of angiotensin II-receptor blockers

American Journal of Health-System Pharmacy

Volumn 62, Issue 22, 2005, Pages 2381-2385

  Young, Christopher H ^a   Zhang, Kui ^a   Poret, Amy W ^b  

^a Caremark   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Angiotensin antagonists; Candesartan; Combined therapy; Diuretics; Drug use; Hypertension; Irbesartan; Losartan; Telmisartan; Valsartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; COMORBIDITY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 28244470990     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040583     Document Type: Article

References (22)

1. Martin J, Krum H. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. Pharmacol Res. 2002; 46: 203-12.
2. See S, Stirling AL. Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health-Syst Pharm. 2000; 57:739-46.
3. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs. 2001; 61:1501-29.
4. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001; 103:904-12.
5. Drug facts and comparisons. St. Louis: Wolters Kluwer; 2004.
6. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA. 2003; 289:2560-72.
7. Medscape. Angiotensin II receptor blockade resource center. www.medscape.com/pages/editorial/resourcecenters/public/arb/rc-arb.ov (accessed 2004 Aug 2).
8. Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health-Syst Pharm. 2001; 58:671-83.
9. [Erratum, Am J Health-Syst Pharm. 2001; 58:1658.]
10. Stoukides CA, McVoy HJ, Kaul AF. Candesartan cilexetil: an angiotensin II receptor blocker. Ann Pharmacother. 1999; 33: 1287-98.
11. Greathouse M. A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations? Congest Heart Fail. 2002; 8:313-20.
12. Hedner T, Oparil S, Rasmussen K et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999; 12:414-7.
13. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998; 7:53-9.
14. Kassler-Taub K, Littlejohn T, Effiott W et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 1998; 11:445-53.
15. [Erratum, Am J Hypertens. 1998; 11:736.]
16. Oparil S, Guthrie R, Lewin AJ et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Clin Ther. 1998; 20:398-409.
17. Mallion J, Sicehe J, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999; 13:657-64.
18. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs healthcare system. Ann Pharmacother. 2002; 36:986-91.
19. Takiya LN, Peterson AM, Finley RS. Meta-analysis of interventions for medication adherence to antihypertensives. Ann Pharmacother. 2004; 38:1617-24.
20. Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002; 24:302-16.
21. Wogen J, Kreilick CA, Livornese RC et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2003; 9:424-9.
22. Ben-Akiva M, Lerman S. Discrete choice analysis. Cambridge, MA: MIT Press; 1994:103-4.